Provider use of preventive strategies for radiocontrast nephropathy in high-risk patients

Nephron Clin Pract. 2004;96(2):c56-62. doi: 10.1159/000076400.

Abstract

Background/aims: Radiocontrast nephropathy (RCN) is a common and costly form of acute renal failure. Current preventative strategies include the use of intravenous (IV) fluids and the discontinuation of nephrotoxic medications at the time of radiocontrast administration. We sought to determine whether providers employ these strategies in high-risk patients to limit the development of RCN.

Methods: High-risk patients undergoing procedures using radiocontrast media over a 12-month period were identified. Medical records were reviewed for all subjects who developed RCN and a randomly selected 25% of patients without RCN. Patients with a contraindication to IV volume expansion were excluded. Medical records of the remaining patients were reviewed to determine whether IV fluids were administered and whether NSAIDs or COX-2 inhibitors were prescribed at the time of contrast administration.

Results: RCN developed in 8% of patients overall. Of 144 patients eligible for IV volume expansion, 16% failed to receive any IV fluids. When IV fluids were employed, their dose and timing of administration varied significantly by treating specialty and procedure. NSAIDs and COX-2 inhibitors were prescribed to 8% of patients.

Conclusions: Commonly accepted strategies for the prevention of RCN are underutilized. Quality improvement efforts are needed to increase the use of these two simple prophylactic measures.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acute Kidney Injury / etiology*
  • Acute Kidney Injury / prevention & control*
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Contrast Media / adverse effects*
  • Cyclooxygenase Inhibitors / therapeutic use
  • Female
  • Fluid Therapy
  • Humans
  • Male
  • Radiopharmaceuticals / adverse effects*
  • Retrospective Studies
  • Risk Factors
  • Withholding Treatment

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Contrast Media
  • Cyclooxygenase Inhibitors
  • Radiopharmaceuticals